Clinical Trials Logo

Clinical Trial Summary

Background and Aim. The new and advanced hybrid closed loop (AHCL) system MiniMed 780G automatically adjusts basal insulin delivery in addition to automated bolus corrections, based on continuous glucose monitoring (CGM) readings, to offer protection against both hyperglycemia and hypoglycemia. The objective of this study is to evaluate whether a simplified approach for patients' follow up using preset of pump settings and a simplified meal announcement, followed by minimal interaction can achieve similar glycemic control of AHCL system MiniMed 780G with Guardian Sensor 4 than a regular protocol that is currently used in adolescents with Type 1 Diabetes (T1D). Methods. This study is Randomized Clinical Trial, two arm, single-center, clinical investigation in subjects with type 1 diabetes on AHCL insulin pump in a period of 3 months. A total of 34 individuals (age 12-18 years) will be enrolled to reach 30 individuals who will complete the 3 months study. Participants will be randomized in two groups: Group 1, Regular Clinical Protocol, 17 participants and Group 2, Simplified Clinical Protocol, 17 participants. All patients will be recruited during the regular clinic visits to the outpatient Endocrine Clinics at Sidra Medicine in Doha. Patients will be chosen on a first-come first-served basis. Inclusion criteria: Clinical diagnosis of type 1 diabetes, , Age 12-18 years, Basal Bolus therapy >8.0 units per day. Exclusion criteria: Diabetic Ketoacidosis (DKA) in the 6 months prior to screening visit. The initiation protocol consists of four stages: HCL system compatibility assessment, HCL system training, Manual Mode Start and Auto Mode start. Patients will have 7 visits in a period of 3 months after initiation of insulin pump therapy. Pump initiation: Group 1, Finetune ICR, Target 100 or 110 mg/dl and AIT: 2-3 hour and Group 2, Carb Ratio by formula 360 / TDD, ICR 8-10 (TDD 40-60), ICR 5-7 (TDD >60), Target 100 mg/dl, AIT: 2 hours with fixed meals Results. No group difference in Time in Range (TIR) (70-180mg/dl) > 70% and HbA1c < 7.5% in a period of 3 months after initiation of AHCL. Conclusion. Conclusions will be drawn on completion of the study and evaluation of the results.


Clinical Trial Description

This study is Randomized Clinical Trial, two arm, single-center, clinical investigation in subjects with type 1 diabetes on AHCL insulin pump in a period of 3 months. A total of 34 individuals (age 12-18 years) will be enrolled to reach 30 individuals who will complete the 3 months study. Participants will be randomized in two groups: - Group 1, Regular Clinical Protocol, 17 participants - Group 2, Simplified Clinical Protocol, 17 participants Intervention Description - Intervention in Group 2, Simplified protocol. - Insulin Carb Ratio (ICR) by formula 360 / Total Daily Dose (TDD) - ICR 8-10 (TDD 40-60) - ICR 5-7 (TDD >60) - Target 100 mg/dl - Active Insulin Time (AIT): 2 hours - Meals: Thee sets of meal set of meals announcement carbs calculated by the following formula: - Regular meal: Total Carbs per Day x 0.6 / 3 - Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 - Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5 * Efficacy The efficacy shall be measured Time in Ranges (provided by CGM data), for Time in Range (70-180mg/dl), Time below Range(<70mg/dl) and Time above Range (>180 mg/dl) in the third month of the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05069727
Study type Interventional
Source Sidra Medical and Research Center
Contact
Status Completed
Phase N/A
Start date November 21, 2021
Completion date August 31, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05437913 - Protocol for Self-Compassion Intervention for Teens With Diabetes Type 1 and Their Caregivers N/A
Recruiting NCT03565770 - Assessment of Individual Follow-up by Coaching Program for Type 1 Diabetes Children N/A
Not yet recruiting NCT05990933 - Role of Adrenaline in in the Inflammatory Response in Diabetes N/A
Completed NCT03751007 - A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) Phase 1/Phase 2
Recruiting NCT06190756 - Impact of Gravity on Cardiac Hemodynamics N/A
Recruiting NCT05866536 - Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years Phase 2
Completed NCT04635280 - Evaluation of Satisfaction Regarding Home Healthcare Provider (HHP) Management of Type 1 Diabetic Patients Using a Closed-loop Automatic Insulin Delivery System N/A
Completed NCT05168657 - Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth N/A
Active, not recruiting NCT05574062 - Evaluation of the MiniMed 780 System in Paediatric Subjects N/A
Recruiting NCT05180591 - Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes Phase 2
Recruiting NCT05176795 - Host-microbiota-environment Interactions
Completed NCT05284071 - Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation N/A
Completed NCT05933460 - Crocus Sativus Extract Impact in Metabolic Control of Patients With Diabetes Mellitus Type 1 N/A
Not yet recruiting NCT04772729 - Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes? Phase 4
Not yet recruiting NCT03170089 - Oral Health Awareness and Oral Hygiene in Insulin Dependent Diabetes Mellitus N/A
Not yet recruiting NCT05669547 - Dual Hormone Closed Loop in Type 1 Diabetes N/A
Recruiting NCT04311021 - Current State of Impaired Awareness of Hypoglycaemia in People With Type 1 Diabetes
Recruiting NCT02685449 - Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps. Phase 4
Completed NCT03956173 - Hypoglycemia and Cardiac Arrhythmias in Type 1 Diabetes
Active, not recruiting NCT05349591 - cePolyTregs in Islet Transplantation Phase 1